Erratum

Weise JC, Srasuebkul P, Trollor JN. Potentially preventable hospitalisations of people with intellectual disability in New South Wales. Med J Aust 2021; 215: 31‐36. https://doi.org/10.5694/mja2.51088 The authors have identified three minor errors in the code used to define potentially preventable hospitalisations for people with intellectual disability: For diabetes complications, the use of level 3 instead of level 4 ICD‐10 codes. For the non‐vaccine preventable pneumonia, a missing decimal point for the J15.7 code (J157 instead of J15.7). For gangrene, the use of a principal diagnosis code for the R02 instead of any diagnosis code. The authors have re‐run their analysis and found minor changes to the rates and trends of potentially preventable hospitalisation for people with intellectual disability: Including diabetes complications has changed the overall rates of chronic disease; chronic disease admission rates are now higher for people with intellectual disability. A small increase in the number admissions related to non‐vaccine‐preventable pneumonia. No difference in the result for gangrene‐related admission, as the numbers remain too low to include in our results. The new information, which does not change the overall findings and discussion, is reflected in the changes to the Abstract, the Results section, Boxes 1 to 3, and the Supporting Information described below. In the Abstract, the Results paragraph should read: Results: The annual age‐standardised rate for people with intellectual disability ranged between 5889 and 7203 per 100 000 persons, and for the NSW population between 1278 and 1511 per 100 000 persons; the rate ratio (RR) ranged between 3.9 (95% CI, 3.7–4.1) in 2014–15 and 5.0 (95% CI, 4.6–5.4) in 2002–03. The difference was greatest for admissions with acute conditions (RR range: 5.4 [95% CI, 5.0–5.8] in 2014–15 to 8.1 [95% CI, 7.4–8.8] in 2002–03). By specific condition, the highest age‐standardised rate was for admissions with convulsions and epilepsy (all years, 2567 per 100 000 population; v NSW population: RR, 22.2; 95% CI, 21.3–23.1). In the Results section, page 32, the first paragraph should read: Between 2001–02 and 2014–15, the age‐standardised rate of potentially preventable hospitalisations of people with intellectual disability ranged between 5889 and 7203 per 100 000 persons; the age‐standardised rate for the NSW population ranged between 1278 and 1511 per 100 000 persons. RRs ranged between 3.9 (95% CI, 3.7–4.1) in 2014–15 and 5.0 (95% CI, 4.6–5.4) in 2002–03 (Box 1, Box 2, A; Supporting Information, table 2). In the Results section, page 32, the second paragraph should read: RRs for potentially preventable hospitalisations for vaccine‐preventable conditions ranged between 2.1 (95% CI, 1.6–3.0) in 2007–08 and 3.4 (95% CI, 2.2–5.2) in 2004–05 (Box 1, Box 2, B; Supporting Information, table 2). For acute conditions, RRs ranged between 5.4 (95% CI, 5.0–5.8) in 2014–15 and 8.1 (95% CI, 7.4–8.8) in 2002–03 (Box 1, Box 2, C; Supporting Information, table 2). For chronic conditions, RRs ranged between 2.0 (for several years) and 2.5 (95% CI, 2.1–2.8) in 2004–05 (Box 1, Box 2, D; Supporting Information, table 2). In the Results section, pages 32 to 33, the final two paragraphs should read: In each age group, the difference in rates of potentially avoidable hospitalisations for people with intellectual disability and for the general NSW population was greatest for convulsions or epilepsy (all ages: RR, 22.2; 95% CI, 21.3–23.1). The second greatest differences were for bronchiectasis for people aged 0–14years (RR, 10.0; 95% CI, 4.1–24.7), 15–24years (RR, 14.5; 95% CI, 5.2–40.5), or 25–44years (RR, 11.7; 95% CI, 4.6–29.7), diabetes complications for people aged 45–64years (RR, 6.5; 95% CI, 5.4–7.8), and pelvic inflammatory disease for people aged 65years or more (RR, 9.0; 95% CI, 1.2–65) (Box 3; Supporting Information, table 3). In each age group, potentially avoidably hospitalisations of people with intellectual disability for asthma were less frequent than for the general NSW population (all ages: RR, 0.4; 95% CI, 0.4–0.4) (Box 3; Supporting Information, table 3). Box 1 – Rate ratios (with 95% confidence intervals) for potentially preventable hospitalisations (per 100000 persons) of New South Wales people with intellectual disability and of all New South Wales people, by year* Year All conditions Vaccine‐preventable conditions Chronic conditions Acute conditions 2001–02 4.9 (4.5–5.3) 3.2 (2.2–4.7) 2.1 (1.8–2.5) 7.7 (7.0–8.4) 2002–03 5.0 (4.6–5.4) 2.6 (1.7–3.8) 2.0 (1.7–2.3) 8.1 (7.4–8.8) 2003–04 4.9 (4.6–5.3) 2.8 (2.1–3.8) 2.4 (2.0–2.7) 7.5 (6.9–8.3) 2004–05 4.9 (4.6–5.3) 3.4 (2.2–5.2) 2.5 (2.1–2.8) 7.5 (6.9–8.2) 2005–06 4.9 (4.6–5.3) 2.7 (1.8–4.1) 2.4 (2.1–2.8) 7.5 (6.9–8.1) 2006–07 4.9 (4.6–5.3) 2.2 (1.5–3.4) 2.3 (2.0–2.6) 7.7 (7.1–8.4) 2007–08 4.4 (4.1–4.6) 2.1 (1.6–3.0) 2.0 (1.7–2.2) 6.8 (6.3–7.4) 2008–09 4.4 (4.2–4.7) 2.6 (1.8–3.9) 2.1 (1.9–2.4) 6.9 (6.3–7.4) 2009–10 4.3 (4.1–4.6) 2.4 (1.8–3.2) 2.3 (2.0–2.6) 6.6 (6.1–7.1) 2010–11 4.6 (4.4–5.0) 2.3 (1.6–3.1) 2.2 (1.9–2.5) 6.5 (6.0–7.1) 2011–12 4.6 (4.3–4.9) 2.7 (1.9–3.7) 2.2 (1.9–2.5) 6.4 (6.0–7.0) 2012–13 4.5 (4.2–4.8) 2.8 (2.1–3.7) 2.0 (1.8–2.3) 6.5 (6.0–7.0) 2013–14 4.2 (3.9–4.4) 2.9 (2.3–3.8) 2.3 (2.1–2.6) 5.8 (5.4–6.2) 2014–15 3.9 (3.7–4.1) 2.8 (2.2–3.5) 2.2 (2.0–2.5) 5.4 (5.0–5.8) * All age‐adjusted rates of potentially preventable hospitalisations by category and year are available in the online Supporting Information, table 2. Box 2 – Age‐adjusted rates of potentially preventable hospitalisations, New South Wales, 2001–02 to 2014–15 Box 3 – Rate ratios (with 95% confidence intervals) for potentially preventable hospitalisations (per 100000 persons) of New South Wales people with intellectual disability and of all New South Wales people, 2010–11 to 2014–15, by age and condition* Condition All ages 0–14years 15–24years 25–44years 45–64years 65years or more Vaccine‐preventable Pneumonia and influenza 2.9 (2.6–3.3) 4.8 (3.9–6.0) 3.9 (2.2–6.8) 4.2 (2.8–6.4) 3.3 (2.2–4.8) 1.4 (0.9–2.1) Other 2.6 (2.2–2.9) 2.1 (1.7–2.7) 1.7 (0.8–3.6) 2.7 (1.9–3.8) 2.7 (2.0–3.6) 2.7 (1.5–5.0) Chronic conditions† Asthma 0.4 (0.4–0.4) 0.1 (0.1–0.1) 0.3 (0.2–0.3) 0.3 (0.2–0.4) 0.4 (0.3–0.6) 0.2 (0.2–0.4) Bronchiectasis 2.6 (2.1–3.2) 10.0 (4.1–24.7) 14.5 (5.2–40.5) 11.7 (4.6–29.7) 1.9 (1.1–3.6) 1.2 (0.7–2.1) Diabetes complications 3.3 (3.1–3.5) 1.6 (1.3–2.0) 2.2 (1.8–2.8) 8.3 (6.6–10.4) 6.5 (5.4–7.8) 3.2 (2.6–4.1) Chronic obstructive pulmonary disease 2.2 (2.1–2.4) 3.0 (1.2–7.5) 5.1 (1.3–20.9) 5.3 (3.0–9.2) 2.9 (2.4–3.4) 2.0 (1.8–2.3) Iron deficiency anaemia 1.8 (1.6–1.9) 3.3 (1.8–6.1) 1.3 (0.9–1.9) 1.9 (1.5–2.4) 1.8 (1.5–2.2) 1.2 (1.0–1.5) Rheumatic heart diseases 1.2 (0.8–1.6) 2.1 (0.7–6.6) 1.7 (0.3–9.8) 1.6 (0.4–6.6) 0.8 (0.3–1.9) 0 Acute conditions‡ Convulsions and epilepsy 22.2 (21.3–23.1) 14.8 (13.7–16.0) 22.6 (19.4–26.3) 25.7 (22.2–29.7) 25.4 (21.6–29.9) 11.9 (8.8–16.3) Dental conditions 5.6 (5.4–5.9) 3.1 (2.9–3.3) 7.2 (6.3–8.4) 11.1 (9.7–12.8) 6.4 (5.4–7.5) 2.3 (1.6–3.2) Ear, nose, throat infections 2.8 (2.7–2.9) 2.5 (2.3–2.7) 1.5 (1.3–1.9) 2.4 (1.9–3.1) 3.6 (2.5–5.3) 2.2 (1.3–3.7) Pelvic inflammatory disease 0.8 (0.7–0.9) 1.2 (0.1–10.7) 0.6 (0.4–1.0) 0.8 (0.5–1.1) 0.2 (0.1–0.4) 9.0 (1.2–64.7) Perforated/bleeding ulcer 1.8 (1.5–2.3) 2.7 (0.1–58.8) 1.6 (0.5–5.4) 1.6 (0.8–3.2) 2.7 (1.6–4.5) 1.4 (0.9–2.4) Pneumonia (not vaccine‐preventable) 2.7 (2.1–3.4) 2.0 (1.4–2.9) 2.8 (0.9–8.4) 4.9 (1.7–14.6) 3.5 (1.1–11.1) 2.1 (0.6–7.5) Urinary tract infections 3.4 (3.2–3.6) 2.4 (2.1–2.7) 2.2 (1.8–2.6) 4.1 (3.4–5.0) 5.3 (4.5–6.4) 2.6 (2.3–3.0) * All age‐adjusted rates of potentially preventable hospitalisations by category and year are available in the online Supporting Information, table 3. † Data for nutritional deficiencies not included because of small case numbers. ‡ Data for eclampsia and gangrene not included because of small case numbers. The category "Convulsions and epilepsy" is included under acute conditions in the National Healthcare Agreement list of potentially preventable hospitalisations.12

Chung E, Lowy M, Gillman M, et al. Urological Society of Australia and New Zealand (USANZ) and Australasian Chapter of Sexual Health Medicine (AChSHM) for the Royal Australasian College of Physicians (RACP) clinical guidelines on the management of erectile dysfunction. Med J Aust 2022; 217: 318‐324. https://doi.org/10.5694/mja2.51694 In these Guidelines, the affiliations for Darren Katz should be: “Men’s Health Melbourne, Melbourne, VIC; University of Melbourne, Melbourne, VIC; and Western Health, Melbourne, VIC”.

Harris MG, Hobbs MJ, Burgess PM, et al. Frequency and quality of mental health treatment for affective and anxiety disorders among Australian adults. Med J Aust 2015; 202: 185‐189. https://doi.org/10.5694/mja14.00297. On page 187, “This equates to 26% and 16%, respectively, of all consultees with a past‐year affective or anxiety disorder” should read: “This equates to 26% and 16%, respectively, of all adults with a past‐year affective or anxiety disorder.” On page 189, “…we might speculate that 19% of consultees with affective and/or anxiety disorders received adequate treatment in 2009–10” should read: “…we might speculate that 19% of adults with affective and/or anxiety disorders received adequate treatment in 2009–10”.

Fitzmaurice L, Donald K, de Wet C, Palipana D. Why we should and how we can increase medical school admissions for persons with disabilities. Med J Aust 2021; 215: 249–251.e1. https://doi.org/10.5694/mja2.51238. In this Perspective article, on page 250, the publication date for the Inclusive medical education: Guidance on medical program applicants and students with disabilities is incorrect. The sentence should read, “Beginning in 2019, MDANZ has been looking to support medical schools build ‘greater inclusivity within their culture, systems, and environment’, and published, in 2021, Inclusive medical education: Guidance on medical program applicants and students with disabilities”.

Chen VM, Curnow JL, Tran HA, Choi PY‐I. Australian and New Zealand approach to diagnosis and management of vaccine‐induced immune thrombosis and thrombocytopenia. Med J Aust 2021; 215: 245–249.e1. https://doi.org/10.5694/mja2.51229. Throughout this Perspective article, an incorrect acronym (“THSANZ”) was used for the Thrombosis and Haemostasis Society of Australia and New Zealand. The correct acronym is “THANZ”.

Allard NL, MacLachlan JH, Tran L, et al. Time for universal hepatitis B screening for Australian adults. Med J Aust 2021; 215: 103‐105.e1. https://doi.org/10.5694/mja2.51114. In this Perspective article, in the Box on page 104, the colour blue in the legend should read, “Number of people with chronic hepatitis B diagnosed (modelled)”, and the red colour should read, “Number of people with chronic hepatitis B undiagnosed (modelled).”

Lubel JS, Roberts SK, Strasser SI, et al. Australian recommendations for the management of hepatocellular carcinoma: a consensus statement. Med J Aust 2021; 214: 475‐483. https://doi.org/10.5694/mja2.50885 In this Consensus statement, on page 475, where it says “These recommendations summarise the complete document, available at https://www.gesa.org.au/resources/hepatocellular-carcinoma-hcc-management-consensus/”, it should read: “These recommendations summarise the complete document, available at https://www.gesa.org.au/resources/hepatocellular-carcinoma-hcc-management-consensus/. The full list of endorsements is available in the online Supporting Information”. An online Supporting Information document has also been added.

Burrell AJC, Pellegrini B, Salimi F, et al. Outcomes for patients with COVID‐19 admitted to Australian intensive care units during the first four months of the pandemic. Med J Aust 2021; 214: 23–30. https://doi.org/10.5694/mja2.50883. In the Results, paragraph 1, the final sentence should read: “The most frequently reported ICU nurse to patient ratios were 1:1 on 1766 of 2270 patient‐days (77.8%) and 2:1 on 171 patient‐days (7.5%).

Chakrabarti R, George G, Wells K, Crock C. Characteristics, treatment and complications of herpes zoster ophthalmicus at a tertiary eye hospital. Med J Aust 2020; 213: 226–227. https://doi.org/10.5694/mja2.50554. The author and affiliations list for this Research letter was incomplete. It should read: Rahul Chakrabarti,1 Grace George,1,2 Kristen Wells,1 Carmel Crock,1 Eamonn Fahy1 1 Royal Victorian Eye and Ear Hospital, Melbourne, VIC. 2 Newcastle University, Newcastle‐upon‐Tyne, United Kingdom.

Dudley MJ, Lin PI. Preventing suicide by young people requires integrative strategies. Med J Aust 2021; 214: 125–126. https://doi.org/10.5694/mja2.50939. The second last sentence of the fifth paragraph was incorrect. It should read: However, inadequate knowledge about mental health services is a problem for one‐third of parents and carers who do not obtain the help their children and adolescents with mental disorders need. Also, reference 14 was incorrect. It should read: Lawrence D, Johnson S, Hafekost J, et al. The mental health of children and adolescents: report on the second Australian Child and Adolescent Survey of Mental Health and Wellbeing (here: p. 86). Aug 2015. https://www.health.gov.au/internet/main/publishing.nsf/Content/9DA8CA21306FE6EDCA257E2700016945/%24File/child2.pdf (viewed Dec 2020).

Kanjanapan Y, Yip D. Considerations for cancer immunotherapy during the COVID‐19 pandemic. Med J Aust 2020; 213: 390‐392. https://doi.org/10.5694/mja2.50805 In this Perspective, on page 391, the sentence “Current guidelines recommend ICI monotherapy to be delivered at increased dosing intervals, such as nivolumab four times per week and pembrolizumab six times per week” is incorrect. It should read: “Current guidelines recommend ICI monotherapy to be delivered at increased dosing intervals, such as nivolumab every four weeks and pembrolizumab every six weeks”.

Jeffrey GP. Hepatocellular carcinoma surveillance in Australia: time to improve the diagnosis of cirrhosis and use liver ultrasound. Med J Aust 2020; 213: 432. https://doi.org/10.5694/mja2.50808 In this reply letter, the authorship details listed were incorrect. The Author details section should read: “Gary P Jeffrey,1,2 Louisa Gordon,3,4 Grant Ramm.3,4”. The affiliations list should read: “1 Sir Charles Gairdner Hospital, Perth, WA; 2 University of Western Australia, Perth, WA; 3 QIMR Berghofer Medical Research Institute, Brisbane, QLD; 4 University of Queensland, Brisbane, QLD”.

Haworth NL, Schramm A. Illegal and risky riding of electric scooters in Brisbane. Med J Aust 2019; 211: 412–413. https://doi.org/10.5694/mja2.50275. In this Research letter, information provided in the third paragraph and Box was wrong. The correct information is shown below. Between Monday 18 and Thursday 21 February 2019, we observed 801 e‐scooters (including 711 commercial shared e‐scooters, 89%), as well as 3062 bicycles (274 shared, 9%) at six locations in central Brisbane during the periods 7–11 am and 2–6 pm. Most riders (625, 88%) were adults and 533 (75%) were boys or men; the proportion of riders under 18 years of age was greater than for share bicycles (11% v 2%). Almost half the shared e‐scooters (342, 48%) were ridden illegally (rider under age, not wearing a helmet, riding on the road, or doubling a passenger), as were eleven private e‐scooters (12%); correct helmet use was less common than for share bicycle riders (81%). Not wearing a properly fastened helmet (no helmet or helmet not properly fastened) was the most frequent risky behaviour, and was again more common among shared than private e‐scooter riders (277 shared e‐scooter riders [39%], four private e‐scooter riders [4%]) (Box). Box – Characteristics of scooter and bicycle riders during peak morning and evening traffic periods at six sites in Brisbane, 18–21 February 2019* Characteristic E‐Scooters Bicycles Shared Private Shared Private Total number 711 90 274 2788 Sex Males 533 (75.0%) 69 (77%) 195 (71%) 2332 (83.6%) Females 172 (24.2%) 21 (23%) 79 (29%) 451 (16.2%) Missing data 6 (0.8%) 0 0 5 (0.2%) Age group Child (under 13 years) 7 (1%) 1 (1%) 0 1 (< 0.1%) Adolescent (13–17 years) 68 (9.6%) 2 (2%) 4 (2%) 21 (0.8%) Adult 625 (87.9%) 86 (96%) 268 (98%) 2750 (98.6%) Missing data 11 (1.5%) 1 (1%) 2 (0.7%) 16 (0.6%) Where ridden Footpath 655 (92.1%) 86 (96%) 152 (55.5%) 740 (26.5%) Road 48 (6.8%) 4 (4%) 122 (44.5%) 2045 (73.4%) Missing data 8 (1%) 0 0 3 (0.1%) Time* 7–9 am 144 [10.9%] 27 [2.0%] 74 [5.6%] 1079 [81.5%] 9–11 am 190 [41.0%] 7 [2%] 52 [11%] 214 [46.2%] 2–4 pm 275 [39.7%] 12 [1.7%] 52 [7.5%] 353 [51.0%] 4–6 pm 102 [7.4%] 44 [3.2%] 96 [6.7%] 1142 [82.5%] Helmet use Helmet correctly worn 433 (60.9%) 86 (96%) 223 (81%) 2734 (98.1%) No helmet 253 (35.6%) 4 (4%) 46 (17%) 34 (1.2%) Worn, but not fastened 24 (3.4%) 0 5 (2%) 10 (0.4%) Missing data 1 (0.1%) 0 0 10 (0.4%) Passenger “doubling” 14 (2.0%) 0 0 0 * Proportions are for columns, except for “Time”, for which proportions of vehicles during period are given.

Brewster DJ, Chrimes N, Do TBT, et al. Consensus statement: Safe Airway Society principles of airway management and tracheal intubation specific to the COVID‐19 adult patient group. Med J Aust 2020; 212: 472–481. https://doi.org/10.5694/mja2.50598. In this Consensus statement, on page 474, on the first paragraph, where it says: “All recommendations were debated extensively. Some of the endorsing societies — ANZICS and the Australian Society of Anaesthetists — were consulted during the development of the document to allow external opinion”, it should read: “All recommendations were debated extensively. They have been recommended by the COVID‐19 Critical Care Coordination Collaborative (5Cs), and have been widely endorsed by relevant specialty colleges and societies (Supporting Information). Some of the endorsing societies — ANZICS and the Australian Society of Anaesthetists — were consulted during the development of the document to allow external opinion”.

Patel C, Chiu CK, Beard FH, et al. One disease, two vaccines: challenges in prevention of meningococcal disease. Med J Aust 2020; 212: 453–456.e1. https://doi.org/10.5694/mja2.50567. In this Perspective article, in Box 1 on page 454, on the x‐axis, where it says: “<12 months, 12–23 months, 2–4 months, 5–9 months, 10–14 months, 15–19 months, 20–24 months, 25–44 months, 45–64 months, ≥65 months”, it should read: “<12 months, 12–23 months, 2–4 years, 5–9 years, 10–14 years, 15–19 years, 20–24 years, 25–44 years, 45–64 years, ≥65 years”.

Akram F, Sadashiv RG. May–Thurner syndrome: an overlooked cause of venous thromboembolism. Med J Aust 2020; 212: 402–403.e1. https://doi.org/10.5694/mja2.50548. In this Perspective article, the Box title should read: “Computed tomography (CT) venogram image showing maximally compressed left common iliac vein (blue arrow) and distal abdominal aorta just before it bifurcates (red arrow). The sequential CT images (not shown) demonstrate a thrombus in the external iliac vein and left common iliac vein as it passes posterior to the proximal right common iliac artery, suggestive of May–Thurner syndrome”.

Bladin CF, Kim J, Bagot KL, et al. Improving acute stroke care in regional hospitals: clinical evaluation of the Victorian Stroke Telemedicine program. Med J Aust 2020; 212: 371–377. https://doi.org/10.5694/mja2.50570. In Box 2 of this article, the heading should read “Control”, not “Contriol”; the author affiliation 3 should read “Monash University, Melbourne, VIC.”, not “Monash Health, Monash University, Melbourne, VIC.”

Huyen A Tran, Harry Gibbs, Eileen Merriman, et al. New guidelines from the Thrombosis and Haemostasis Society of Australia and New Zealand for the diagnosis and management of venous thromboembolism. Med J Aust 2019; 210: 227‐235. https://doi.org/10.5694/mja2.50004 In this Guideline summary, the Competing interests section should read: “Huyen Tran, Harry Gibbs, Jennifer Curnow, Chee Wee Tan, Sanjeev Chunilal, Ross Baker, Chris Ward and Harshal Nandurkar have received study grants and/or personal fees from Bayer Health, Boehringer Ingelheim, Pfizer, Sanofi and Aspen and have served on advisory boards for these companies. However, no financial or other support was sought from or provided by these or other commercial bodies for the preparation of the guidelines or this guideline summary”.

Beard FH, Hendry AJ, Macartney K. Early success with room for improvement: influenza vaccination of young Australian children. Med J Aust 2019; 210: 484–486. https://doi.org/10.5694/mja2.50141 In this Perspective article, the Box title should read: “Australian cumulative coverage estimates* of at least one dose of influenza vaccine from the Australian Immunisation Register in 2018 (1 April to 30 September) for children aged 6 months to less than 5 years, by age group, for all children (A) and Indigenous children (B) and by jurisdiction (inserts), assessed at 30 September 2018”.

Erratum Kim J, Ussher JG. Orbital rhabdomyosarcoma: a rare ophthalmic condition. Med J Aust 2019; 211: 398‐399. https://doi.org/10.5694/mja2.50365 In this Lessons from practice article, the fifth sentence in the second paragraph on page 398 should read: “A suspicion for orbital rhabdomyosarcoma was raised and an urgent magnetic resonance imaging scan was performed”. In Box 3 on page 399, the title should read: “Coronal view of magnetic resonance imaging scan of the orbits. The rhabdomyosarcoma tumour is located in the superonasal aspect of the right orbit”.

Warrillow S, Raper R. The evolving role of intensive care in health care and society. Med J Aust 2019; 211: 294‐297. https://doi.org/10.5694/mja2.50340 In this Perspective article, in Box 3 on page 295, the number of ICU beds in Western Australia should read: “162 ICU beds”.

Tran HA, Gibbs H, Merriman E, et al. New guidelines from the Thrombosis and Haemostasis Society of Australia and New Zealand for the diagnosis and management of venous thromboembolism. Med J Aust 2019; 210: 227‐235. https://doi.org/10.5694/mja2.50004 The name of author Chee Wee Tan was reversed at original publication and has been corrected online. ◆

Brieger D, D'Souza M, Hyun K, et al. Intensive lipid‐lowering therapy in the 12 months after an acute coronary syndrome in Australia: an observational analysis. Med J Aust 2019; 210: 80‐85. https://doi.org/10.5694/mja2.12035 In the Research article above, the name of the third author was incorrect; her name is Karice Hyun. The change has been made online. ◆

Eisman JA, White CP. Dispelling confusion about de‐prescribing bisphosphonates. Med J Aust 2019; 210: 17‐19. https://doi.org/10.5694/mja2.12058 In the Editorial above, the final clause on page 17 should read: “that is, for someone whose T‐score is better than –2.5, who have not had any recent fractures, and who have no important risk factors, such as ongoing glucocorticoid or sex hormone ablative therapies.” ◆